Coherus Oncology (CHRS) EBT Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) EBT Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 32.96%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 28.95%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 20.92%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -49.71%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 12.01%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Coherus Oncology 199.14 Mn 32.09 Mn 8.50 Mn 21.28%

Historic Data

Download Data
DateValue
Mar 31, 2026 21.28%
Dec 31, 2025 7.66%
Sep 30, 2025 19.91%
Jun 30, 2025 3.65%
Mar 31, 2025 20.99%
Dec 31, 2024 -29.88%
Sep 30, 2024 -7.30%
Jun 30, 2024 -22.42%
Mar 31, 2024 26.73%
Dec 31, 2023 -123.67%
Sep 30, 2023 -50.71%
Jun 30, 2023 -39.43%
Mar 31, 2023 -59.72%
Dec 31, 2022 -50.76%
Sep 30, 2022 -56.18%
Jun 30, 2022 -60.36%
Mar 31, 2022 -68.72%
Dec 31, 2021 80.24%
Sep 30, 2021 13.16%
Jun 30, 2021 11.87%